CARE Ratings Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Technicals and Strong Financials

Quality Assessment: Consistent Financial Performance and Institutional Confidence

CARE Ratings continues to demonstrate robust operational quality, underpinned by its positive financial performance in the second quarter of FY25-26. The company has reported positive results for nine consecutive quarters, signalling sustained business momentum. Notably, the Return on Capital Employed (ROCE) for the half-year period reached a peak of 24.14%, highlighting efficient capital utilisation.

Cash and cash equivalents have also hit a high of ₹286.60 crores, providing a strong liquidity buffer. The company’s net sales for the quarter stood at ₹136.37 crores, marking the highest quarterly sales figure to date. Furthermore, CARE Ratings maintains a low average Debt to Equity ratio of zero, indicating a conservative capital structure with minimal leverage risk.

Institutional holdings remain substantial at 54.3%, reflecting confidence from sophisticated investors who typically conduct thorough fundamental analysis. This institutional backing adds a layer of stability and suggests that the company’s quality metrics are well-regarded by market professionals.

Valuation: Premium Pricing Amidst Strong Returns but Elevated Multiples

Despite the positive quality indicators, valuation remains a key consideration in the rating upgrade. CARE Ratings trades at a Price to Book (P/B) ratio of 5.6, which is significantly higher than the average historical valuations of its peers in the capital markets sector. This premium valuation reflects investor optimism but also raises concerns about the stock’s relative expensiveness.

The company’s Return on Equity (ROE) stands at 17.7%, which is respectable but does not fully justify the elevated P/B multiple. Over the past year, CARE Ratings has delivered a stock return of 17.18%, outperforming the BSE500 benchmark and generating a profit growth of 33.7%. This results in a Price/Earnings to Growth (PEG) ratio of approximately 1, suggesting that the stock’s price growth is roughly in line with its earnings growth, a neutral signal for valuation.

However, the long-term growth rates for net sales and operating profit are moderate, at 13.14% and 17.59% annually over five years respectively. This tempered growth trajectory tempers enthusiasm for the current valuation premium, supporting a Hold rating rather than a Buy.

Financial Trend: Positive Quarterly Results but Mixed Long-Term Growth

CARE Ratings’ recent quarterly results reinforce a positive financial trend, with the company achieving its highest net sales and cash reserves in the latest reporting period. The consistent positive results over nine quarters indicate operational resilience and effective management execution.

However, the longer-term financial growth metrics present a more cautious outlook. While the company has outperformed the Sensex and BSE500 indices over one, three, and five-year periods—with returns of 17.18%, 163.55%, and 231.23% respectively—the underlying sales and profit growth rates are moderate. The annualised net sales growth of 13.14% and operating profit growth of 17.59% over five years suggest steady but unspectacular expansion.

This divergence between strong market returns and moderate fundamental growth underlines the importance of valuation discipline and supports the Hold rating, as investors may be paying a premium for growth that is not accelerating significantly.

Technical Analysis: Shift from Mildly Bullish to Mildly Bearish Signals

The technical landscape for CARE Ratings has shifted, prompting a downgrade in the technical grade that contributed to the overall rating change. The technical trend has moved from mildly bullish to mildly bearish, reflecting a more cautious market sentiment.

Key technical indicators present a mixed picture. On a weekly basis, the MACD and KST indicators remain bullish, suggesting some underlying momentum. However, monthly MACD and KST readings have turned mildly bearish, and the Relative Strength Index (RSI) on a monthly scale is bearish, indicating potential downward pressure.

Bollinger Bands show mild bullishness on both weekly and monthly charts, but daily moving averages have turned mildly bearish. Dow Theory and On-Balance Volume (OBV) indicators show no clear trend on weekly or monthly timeframes, adding to the uncertainty.

Price action reflects this indecision, with the stock currently trading at ₹1,600.65, slightly below its previous close of ₹1,605.35. The 52-week high remains ₹1,964.80, while the low is ₹1,057.65, indicating a wide trading range. Daily price fluctuations between ₹1,577.85 and ₹1,618.90 further illustrate the stock’s volatility.

Comparative Performance: Outperforming Benchmarks but Facing Valuation Headwinds

CARE Ratings has delivered impressive returns relative to the Sensex over multiple time horizons. The stock posted a 1-week return of 1.95% compared to the Sensex’s -1.00%, a 1-month return of 0.95% versus the Sensex’s -4.67%, and a year-to-date return essentially flat at -0.01% against the Sensex’s -5.28%. Over the last year, the stock’s 17.18% return significantly outpaced the Sensex’s 5.16% gain.

Longer-term returns are even more striking, with 3-year and 5-year returns of 163.55% and 231.23% respectively, dwarfing the Sensex’s 35.67% and 74.40% gains. However, the 10-year return of 32.45% trails the Sensex’s 224.57%, indicating that the company’s outperformance is more recent and not sustained over the very long term.

This strong relative performance supports the Hold rating, but the premium valuation and mixed technical signals caution against a more aggressive Buy recommendation at this stage.

Conclusion: Balanced Outlook Justifies Hold Rating

The upgrade of CARE Ratings Ltd from Sell to Hold reflects a balanced reassessment of its investment merits. The company’s strong quality metrics, including consistent positive quarterly results, high ROCE, and robust cash reserves, underpin a solid foundation. Institutional confidence further bolsters this view.

However, the elevated valuation multiples, moderate long-term growth rates, and mixed technical indicators temper enthusiasm. While the stock has outperformed key benchmarks in recent years, the premium pricing and recent shift to mildly bearish technical trends suggest caution.

Investors should monitor CARE Ratings’ financial performance and technical signals closely, particularly given the stock’s volatility and valuation premium. For now, the Hold rating appropriately reflects the company’s current risk-reward profile within the capital markets sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →